| 2 | 1 | 68 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:研究探讨维吾尔族和汉族非小细胞肺癌组织中DNA修复家族成员核苷酸切除修复交叉互补组1(excision repair cross complementation group1,ERCC1)及乳腺癌易感基因(breast cancer susceptibility genel,BRCA1)的表达及其对化疗疗效的预测价值。方法:收集2009年1月-2012年6月经病理证实的初治晚期NSCLC标本200例,其中维吾尔族患者和汉族患者分别为94例和106例,采用免疫组化方法检测ERCC1、BRCA1的表达情况,分析二者表达的特点和相关性。结果:维吾尔族NSCLC组织中ERCC1表达阳性率为31.9%,汉族NSCLC组织中ERCC1表达阳性率为30.2%,两组ERCC1的表达在差异无统计学意义(χ2=0.069,P>0.05);维吾尔族NSCLC组织中BRCA1表达阳性率为80.9%,汉族NSCLC组织中BRCA1表达阳性率为59.4%,两组BRCA1的表达差异有统计学意义(χ2=10.781,P<0.05);在维吾尔族或汉族NSCLC组织中,ERCC1和BRCA1表达差异有统计学意义(χ2=5.726,P<0.05;χ2=6.726,P<0.05),且表达均存在显著负相关(r=-0.247,P<0.05;rs=-0.252,P<0.05)。结论:维吾尔族与汉族NSCLC组织中BRCA1表达存在差异,且ERCC1和BRCA1表达存在负相关。ERCC1和BRCA1可为临床上维吾尔民族非小细胞肺癌患者个体化治疗及判断预后提供参考。
Abstract：Objective:To investigate the differential expression of excision repair cross complementation group 1(ERCC1)and breast cancer susceptibility gene 1(BRCA1)and their prognostic value to chemotherapy in Uygur and Han patients with non-small cell lung cancer(NSCLC).Methods:We sampled the specimens of200(94 Uygur and 106 Han)patients with pathology-diagnosed advanced NSCLC who.were admitted between January 2009 and June 2012.Immunohistochemistry assay was employed to detect the ERCC1 and BRCA1expression for subsequent analysis on their characteristics and correlation.Results:The difference in the positive rate of ERCC1 in NSCLC tissues between Uygur and Han patients were unremarkable(31.9%vs.30.2%,X2=0.069,P>0.05).Uygur patients yielded a significantly higher positive rate of BRCA1 expression in NSCLC tissue than Han patients(80.9%vs.59.4%,X2=10.781,P<0.05).The expression of ERCC1 differed substantially from that of BRCA1 in Uygur(X2=5.726,P<0.05)or Han patients(X2=6.726,P<0.05).A negative correlation was found between ERCC1 and BRCA1 expression in Uygur(rs=-0.247,P <0.05)and Han patients(rs =- 0.252,P < 0.05).Conclusion:The fact that Uygur and Han patients with NSCLC differ substantially in BRCAl expression and that ERCCl expression correlates negatively with BRCAl in NSCLC tissues may shed light on implementation of individualized therapy and judgment of prognosis of chemotherapy in Uygur patients.
[1]Rosell R,Cobo M,Isla D,et al.Pharmacogenomies andgemcitabine[J].Ann Oncol,2006,17(Suppl 5):13-16.
[2]Rinaldi M,Cauchi C,Gridelli C.First line chemotherapy in advanced or metastatic NSCLC[J].Ann Oncol,2006,17(suppl 5):64-67.
[3]Allen J,Jahanzeb M.Neoadjuvant chemotherapy in stageⅢNSCLC[J].J Natl Compr Cane Netw,2008,6(3):285-293.
[4]Wachters FM,WongL SM,Timens W,et al.ERCC1,hRad51,and BRCA1 protein expression in relation to tumour response and survival of stageⅢ/ⅣNSCLC patients treated with chemotherapy[J].Lung Cancer,2005,50(2):211-219.
[5]Taron M,RoseU R,Felip E,et al.BRCA1 mRNA expression levelsasan indicator of chemoresistance in lung cancer[J].Hum Mol Genet,2004,13(20):2443-2449.
[6]Simon GR,Ismai-lKhan R,Bepler G.Nuclear excision repair-based personalized therapy for non-small cell lung cancer:Fromhypothesis to reality[J].Int J Biochem Cell Biol,2007,39(7-8):1318-1328.
[7]Ratnasinghe D,Yao SX,Tangrea JA,et al.Polylmorphisms of the DNA repairgenes and lung cancer risk[J].Caner Epidemiol Biomarkers Prev,2001,10(2):119-123.
[8]吕嘉春,吴中亮.核苷酸切除修复基因表达低下与肺癌的关系[J].中国公共卫生,2003,19(7):780-782.
[9]Olaussen KA,Dunant A,Fouret P,et al.DNArepair by ERCC1 in non-small cell lung cancer and cisplatin based adjuvant chemotherapy[J].N Engl J Med,2006,355(10):983-991.
[10]Miki Y,Swensen J,Shattuck ED,et al.Astrong candidate for the breast and ovarian cancer susceptibility gene BRCA1[J].Science,1994,266(5182):66-71.
[11]Miquel T,Rafael R.BRCA1mRNAexpression levelsasan indica-tor of chemore-sistance in lungcaneer[J].HMol Gene,2004,13(20):2443-2449.
[12]RoseU R,Cobo M,Isla D,et al.Pharmacogenomies and gemcitabine[J].Ann Oncol,2006,17(Suppl 5):13-16.
[13]RoseU R,Skrzypski M,JassemE,et al.BRCA1:anovelprog nosticfactor in resected non-small cell lung cancer[J].PLos One,2007,2(11):ell29.
基本信息:
中图分类号:R734.2
引用信息:
[1]刘莉,单莉,宋云林,等.ERCC1、BRCA1在维族、汉族非小细胞肺癌患者中的表达分析[J].广州医学院学报,2013,41(02):20-23.
基金信息:
新疆医科大学科研创新基金(XJC201031)
2013-04-15
2013-04-15